Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 17/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22103152 | 1.00 | MAT2A (0.51) | MAT2AKDM4EKLK7ALDH1A1LMNA | |
| SCHEMBL22103151 | 0.89 | MAT2A (0.49) | MAT2AKDM4EALDH1A1 | |
| SCHEMBL22103103 | 0.88 | MAT2A (0.56) | MAT2AKDM4EALDH1A1LMNA | |
| SCHEMBL22103307 | 0.84 | MAT2A (0.64) | MAT2A | |
| SCHEMBL29570156 | 0.84 | MAT2A (0.52) | MAT2A | |
| SCHEMBL23549033 | 0.84 | MAT2A (0.52) | MAT2A | |
| SCHEMBL29570678 | 0.84 | MAT2A (0.64) | MAT2A | |
| SCHEMBL22103579 | 0.83 | MAT2A (0.72) | MAT2A | |
| SCHEMBL22094365 | 0.81 | MAT2A (0.56) | MAT2A | |
| SCHEMBL22093169 | 0.79 | MAT2A (0.56) | MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | MAT2A 2/4885KDM4E 1484/4885KLK7 4820/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885KDM4E 1484/4885KLK7 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.